These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15905887)

  • 1. Change in blood pressure predicts regression of cardiac hypertrophy in patients of African ancestry receiving agents influencing the renin-angiotensin system.
    Libhaber EN; Norton GR; Libhaber CD; Candy GP; Woodiwiss AJ; Sliwa K; Essop MR; Sareli P
    J Hum Hypertens; 2005 Aug; 19(8):659-61. PubMed ID: 15905887
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
    Yutaka M; Mifune M; Kubota E; Itoh H; Saito I
    Clin Exp Hypertens; 2009 Nov; 31(8):648-56. PubMed ID: 20001457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.
    Ito N; Ohishi M; Yamamoto K; Tatara Y; Shiota A; Hayashi N; Komai N; Yanagitani Y; Rakugi H; Ogihara T
    Am J Hypertens; 2007 Jul; 20(7):792-9. PubMed ID: 17586415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertension and diabetic nephropathy, a dangerous duo].
    Hausberg M; Hohage H; Kosch M
    Med Klin (Munich); 2005 Nov; 100(11):729-37; quiz 738-9. PubMed ID: 16328181
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination therapy as first-line treatment for hypertension.
    Crawford MH
    Am J Cardiovasc Drugs; 2009; 9(1):1-6. PubMed ID: 19178127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blocking agents in regression of cardiac hypertrophy--how and why?
    Paul B; Goyal RK
    Indian Heart J; 2000; 52(1):19-22. PubMed ID: 10820928
    [No Abstract]   [Full Text] [Related]  

  • 8. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Krauser DG; Devereux RB
    Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations.
    Ruilope LM; Segura J
    Expert Opin Pharmacother; 2010 Nov; 11(16):2619-23. PubMed ID: 20977398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents.
    Hanselin MR; Saseen JJ; Allen RR; Marrs JC; Nair KV
    Hypertension; 2011 Dec; 58(6):1008-13. PubMed ID: 22042809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD
    Am J Hypertens; 2007 Oct; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract]   [Full Text] [Related]  

  • 14. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 15. [Perfect 24-hr blood pressure control using self-measured blood pressure and ambulatory blood pressure monitoring in chronic kidney disease].
    Kario K
    Nihon Jinzo Gakkai Shi; 2009; 51(4):465-70. PubMed ID: 19601555
    [No Abstract]   [Full Text] [Related]  

  • 16. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
    Riva N; Lip GY
    Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
    Tsouli SG; Liberopoulos EN; Kiortsis DN; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):1-15. PubMed ID: 16703216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for hypertension.
    Kaplan NM
    Nat Rev Cardiol; 2009 Apr; 6(4):270-1. PubMed ID: 19352329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.